Latham & Watkins has advised CHEPLAPHARM Arzneimittel GmbH (CHEPLAPHARM), a leading international platform for well-established branded medicines, on the issuance of €750 million aggregate principal amount of New York law 144A/Reg S senior secured notes due May 2030. The issuance comprises €425 million 7.500% senior secured notes and €325 million senior secured floating rate notes. The senior secured notes will be listed on The International Stock Exchange (Official List).
The proceeds will be used to finance the acquisition of the worldwide commercial rights (excluding South Korea) for Zyprexa® from Eli Lilly and Company. The M&A transaction and bridge financing were advised by a team led by Hamburg partner Christoph Engeler and Frankfurt partner Alexandra Hagelüken.
The Latham team was led by Frankfurt partners Rüdiger Malaun and Jan Penselin, with associate Isabel Willius. Advice was also provided on tax matters by Munich partner Ulf Kieker. The Latham team worked closely with CHEPLAPHARM’s in-house team with Head of Legal Jan Klumb and Legal Counsel Anees Ahmed.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
